Table 1 Baseline clinical characteristics based on stratification of LANCL2 expression in the TCGA-STAD cohort.
Characteristic | Low expression of LANCL2 | High expression of LANCL2 | P |
|---|---|---|---|
n | 187 | 188 | |
Age, n (%) | 0.001 | ||
<=65 | 98 (26.4%) | 66 (17.8%) | |
> 65 | 88 (23.7%) | 119 (32.1%) | |
Gender, n (%) | 0.313 | ||
Female | 72 (19.2%) | 62 (16.5%) | |
Male | 115 (30.7%) | 126 (33.6%) | |
T stage, n (%) | 0.164 | ||
T1 | 10 (2.7%) | 9 (2.5%) | |
T2 | 45 (12.3%) | 35 (9.5%) | |
T3 | 89 (24.3%) | 79 (21.5%) | |
T4 | 41 (11.2%) | 59 (16.1%) | |
N stage, n (%) | 0.719 | ||
N0 | 60 (16.8%) | 51 (14.3%) | |
N1 | 49 (13.7%) | 48 (13.4%) | |
N2 | 36 (10.1%) | 39 (10.9%) | |
N3 | 34 (9.5%) | 40 (11.2%) | |
M stage, n (%) | 0.711 | ||
M0 | 165 (46.5%) | 165 (46.5%) | |
M1 | 11 (3.1%) | 14 (3.9%) | |
Pathologic stage, n (%) | 0.164 | ||
Stage I | 28 (8%) | 25 (7.1%) | |
Stage II | 65 (18.5%) | 46 (13.1%) | |
Stage III | 68 (19.3%) | 82 (23.3%) | |
Stage IV | 17 (4.8%) | 21 (6%) | |
Histologic grade, n (%) | 0.440 | ||
G1 | 6 (1.6%) | 4 (1.1%) | |
G2 | 63 (17.2%) | 74 (20.2%) | |
G3 | 114 (31.1%) | 105 (28.7%) | |
H pylori infection, n (%) | 0.023 | ||
No | 67 (41.1%) | 78 (47.9%) | |
Yes | 14 (8.6%) | 4 (2.5%) |
